CLL/SLL

2
Pipeline Programs
4
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

InnoCare
InnoCareChina - Beijing
1 program
1
ICP-022Phase 1/21 trial
Active Trials
NCT03493217Unknown100Est. Dec 2022
H
HutchmedChina - Hong Kong
1 program
1
HMPL-760Phase 11 trial
Active Trials
NCT05176691Withdrawn0Est. Nov 2022
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
First line therapyN/A
AbbVie
AbbVieNORTH CHICAGO, IL
1 program
First line therapyN/A

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
InnoCareICP-022
HutchmedHMPL-760

Clinical Trials (2)

Total enrollment: 100 patients across 2 trials

NCT03493217InnoCareICP-022

A Study to Evaluate ICP-022 in Patients With CLL/ SLL

Start: Apr 2018Est. completion: Dec 2022100 patients
Phase 1/2Unknown
NCT05176691HutchmedHMPL-760

HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL

Start: Feb 2022Est. completion: Nov 20220
Phase 1Withdrawn

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 companies competing in this space